

David G Hicks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11255239/publications.pdf>

Version: 2024-02-01

109
papers

13,736
citations

71102

41
h-index

43889

91
g-index

115
all docs

115
docs citations

115
times ranked

14970
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2-Low Breast Cancers. American Journal of Clinical Pathology, 2022, 157, 328-336.	0.7	39
2	Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience. Cancer Research, 2022, 82, P4-05-09-P4-05-09.	0.9	0
3	HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and Blueprint genomic profiles. Modern Pathology, 2022, 35, 1075-1082.	5.5	53
4	HER2-low breast cancers: Current insights and future directions. Seminars in Diagnostic Pathology, 2022, 39, 305-312.	1.5	20
5	Significance of HER2 in Microinvasive Breast Carcinoma. American Journal of Clinical Pathology, 2021, 156, 155-165.	0.7	9
6	L1CAM Expression in Recurrent Estrogen Positive/HER2 Negative Breast Cancer: A Novel Biomarker Worth Considering. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 287-292.	1.2	7
7	Breast and Gynecologic Tumors. , 2021, , 89-120.		0
8	Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing. American Journal of Clinical Pathology, 2021, 155, 781-792.	0.7	11
9	HER2 Testing. Applied Immunohistochemistry and Molecular Morphology, 2021, Publish Ahead of Print, 635-642.	1.2	2
10	Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. Human Pathology Reports, 2021, 26, 300574.	0.3	5
11	Detailed Morphologic Evaluation of Breast Papillary Lesions on Core Biopsy Is Critical for Accurate Classification and Clinical Management: The Experience of an Academic Institute. Clinical Breast Cancer, 2021, , .	2.4	0
12	Frequency, Clinicopathologic Characteristics, and Follow-up of HER2-Positive Nonpleomorphic Invasive Lobular Carcinoma of the Breast. American Journal of Clinical Pathology, 2020, 153, 583-592.	0.7	8
13	Applying the New Guidelines of HER2 Testing in Breast Cancer. Current Oncology Reports, 2020, 22, 51.	4.0	30
14	Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine. Archives of Pathology and Laboratory Medicine, 2019, 143, 1346-1363.	2.5	78
15	Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma. American Journal of Clinical Pathology, 2019, 151, 461-468.	0.7	9
16	Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMA) and prediction of an Oncotype DX® recurrence score <26. Cancer Medicine, 2019, 8, 4176-4188.	2.8	13
17	Reconsidering "low-risk" criteria for breast cancer recurrence in hormone positive patients. Breast Journal, 2019, 25, 545-547.	1.0	2
18	Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies. Journal of Biomedical Optics, 2019, 24, 1.	2.6	14

#	ARTICLE	IF	CITATIONS
19	A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study. BMC Cancer, 2018, 18, 1266.	2.6	17
20	Molecular Pathology and Pre-Analytic Variables: Impact on Clinical Practice From a Breast Pathology Perspective. Current Pathobiology Reports, 2018, 6, 125-134.	3.4	5
21	p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer. Human Pathology, 2017, 68, 22-25.	2.0	9
22	In Reply. Archives of Pathology and Laboratory Medicine, 2016, 140, 741-741.	2.5	0
23	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2016, 34, 4390-4397.	1.6	51
24	p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?. Human Pathology, 2016, 55, 196-201.	2.0	3
25	Preanalytic Variables, Tissue Quality and Clinical Samples from Breast Cancer Patients: Implications for Treatment Planning, Drug Discovery and Translational Research. , 2016, , 19-26.		2
26	HER2-Positive Carcinoma. , 2016, , 350-359.		0
27	Carcinoma With Extensive Intraductal Component. , 2016, , 382-385.		0
28	HER2. , 2016, , 440-451.		0
29	Myofibroblastoma. , 2016, , 518-525.		0
30	Hormone Receptors (ER/PR). , 2016, , 430-439.		1
31	Introduction: Prognostic and Predictive Factors. , 2016, , 386-393.		0
32	Breast Carcinoma, Male. , 2016, , 660-663.		0
33	Hereditary Breast/Ovarian Cancer Syndrome: *BRCA2*. , 2016, , 650-653.		0
34	Invasive Lobular Carcinoma Variants. , 2016, , 258-263.		0
35	Expression Profiling, Protein. , 2016, , 486-493.		0
36	Expression Profiling, mRNA. , 2016, , 474-477.		0

#	ARTICLE	IF	CITATIONS
37	Basal-Like Carcinoma. , 2016, , 324-331.		0
38	Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients. BMC Clinical Pathology, 2015, 15, 21.	1.8	6
39	Predictive Biomarkers in Breast Cancer: ER, PR and Her-2/neu. , 2015, , 217-233.		0
40	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2015, 33, 2695-2704.	1.6	279
41	Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Modern Pathology, 2015, 28, 921-931.	5.5	70
42	Core vs Breast Resection Specimen: Does It Make a Difference for HER2 Results?. American Journal of Clinical Pathology, 2015, 144, 533-535.	0.7	2
43	American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents. Archives of Pathology and Laboratory Medicine, 2015, 139, 970-971.	2.5	23
44	Reply to E.A. Rakha et al. Journal of Clinical Oncology, 2015, 33, 1302-1304.	1.6	31
45	Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Laboratory Investigation, 2015, 95, 334-341.	3.7	52
46	The Impact of Pre-analytic Variables on Tissue Quality from Clinical Samples Collected in a Routine Clinical Setting: Implications for Diagnostic Evaluation, Drug Discovery, and Translational Research. Methods in Pharmacology and Toxicology, 2014, , 259-270.	0.2	3
47	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Archives of Pathology and Laboratory Medicine, 2014, 138, 241-256.	2.5	961
48	Progress in Implementing HER2 Testing Guidelines. Archives of Pathology and Laboratory Medicine, 2014, 138, 863-864.	2.5	6
49	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast. Archives of Pathology and Laboratory Medicine, 2014, 138, 595-601.	2.5	94
50	A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Laboratory Investigation, 2014, 94, 467-474.	3.7	48
51	Expression of Androgen Receptor and Its Association With Estrogen Receptor and Androgen Receptor Downstream Proteins in Normal/Benign Breast Luminal Epithelium. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 498-504.	1.2	10
52	Reply to R. Bhargava et al and K. Lambein et al. Journal of Clinical Oncology, 2014, 32, 1857-1859.	1.6	3
53	Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression. Histopathology, 2014, 65, 508-516.	2.9	18
54	Standardization of Tissue Handling From the OR to the Laboratory. AORN Journal, 2014, 99, 810-813.	0.3	4

#	ARTICLE	IF	CITATIONS
55	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2013, 31, 3997-4013.	1.6	3,276
56	Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. <i>Modern Pathology</i> , 2013, 26, 1-9.	5.5	88
57	Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1815-1824.	6.3	103
58	Expression of the Androgen Receptor and its Correlation with Molecular Subtypes in 980 Chinese Breast Cancer Patients. <i>Breast Cancer: Basic and Clinical Research</i> , 2012, 6, BCBCR.S8323.	1.1	51
59	Breast and Prostate Cancer in a BRCA2 Carrier. <i>Breast Journal</i> , 2012, 18, 511-513.	1.0	3
60	Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 79-92.	2.8	89
61	Targeted therapies in breast cancer: tailoring treatment to the molecular drivers of disease progression. <i>Medical Laboratory Observer</i> , 2012, 44, 36, 38-9.	0.1	1
62	Immunohistochemistry in the Diagnostic Evaluation of Breast Lesions. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 501-505.	1.2	9
63	HER2 Testing in Gastric and Gastroesophageal Junction Cancers. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2011, 19, 506-508.	1.2	30
64	Breast Cancer Predictive Factor Testing: The Challenges and Importance of Standardizing Tissue Handling. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 43-45.	2.1	24
65	Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry. <i>Laboratory Medicine</i> , 2011, 42, 459-467.	1.2	32
66	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. <i>Breast Cancer: Basic and Clinical Research</i> , 2010, 4, 117822341000400.	1.1	199
67	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2784-2795.	1.6	2,667
68	A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer. <i>Cancer Investigation</i> , 2010, 28, 978-982.	1.3	65
69	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 907-922.	2.5	697
70	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, e48-e72.	2.5	855
71	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. <i>Breast Cancer: Basic and Clinical Research</i> , 2010, 4, 35-41.	1.1	415
72	Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis. <i>Diagnostic Molecular Pathology</i> , 2009, 18, 125-132.	2.1	109

#	ARTICLE	IF	CITATIONS
73	HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment. <i>Oncologist</i> , 2009, 14, 760-768.	3.7	35
74	Dual expression of β -tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of β -tocopherol-associated protein in estrogen-receptor-positive breast carcinomas. <i>Modern Pathology</i> , 2009, 22, 770-775.	5.5	12
75	Benign Inclusion of Axillary Lymph Nodes: Report of Two Cases and Literature Review. <i>Breast Journal</i> , 2009, 15, 664-665.	1.0	6
76	Osteoclastlike giant cell tumor of the salivary gland. <i>Annals of Diagnostic Pathology</i> , 2009, 13, 114-118.	1.3	14
77	Genetic Heterogeneity in <i>HER2</i> Testing in Breast Cancer: Panel Summary and Guidelines. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 611-612.	2.5	211
78	Solitary Fibrous Tumor of the Breast and Mammary Myofibroblastoma: The Same Lesion?. <i>Breast Journal</i> , 2008, 14, 287-292.	1.0	36
79	HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon's Perspective. <i>Annals of Surgical Oncology</i> , 2008, 15, 1677-1688.	1.5	8
80	HER2+ Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2008, 129, 263-273.	0.7	130
81	Breast Cancer Metastasis Suppressor-1 Differentially Modulates Growth Factor Signaling. <i>Journal of Biological Chemistry</i> , 2008, 283, 28354-28360.	3.4	46
82	Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2008, 16, 513-520.	1.2	118
83	Trastuzumab as Adjuvant Therapy for Early Breast Cancer: The Importance of Accurate Human Epidermal Growth Factor Receptor 2 Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 1008-1015.	2.5	49
84	The Role of the Indispensable Surgical Pathologist in Treatment Planning for Breast Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 1226-1227.	2.5	5
85	Recommendations for Improved Standardization of Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2007, 15, 124-133.	1.2	205
86	Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast. <i>Diagnostic Molecular Pathology</i> , 2007, 16, 207-210.	2.1	73
87	The Expression of the Cytoskeletal Focal Adhesion Protein Paxillin in Breast Cancer Correlates with HER2 Overexpression and May Help Predict Response to Chemotherapy: A Retrospective Immunohistochemical Study. <i>Breast Journal</i> , 2007, 13, 130-139.	1.0	37
88	Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 19-30.	2.5	48
89	Automation of Manual Components and Image Quantification of Direct Dual Label Fluorescence In Situ Hybridization (FISH) for HER2 Gene Amplification. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2006, 14, 436-440.	1.2	24
90	Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1097-1104.	3.7	229

#	ARTICLE	IF	CITATIONS
91	A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution. <i>Breast</i> , 2006, 15, 728-735.	2.2	19
92	Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2006, 12, 6702-6708.	7.0	92
93	Metastatic Disease to the Musculoskeletal System. , 2006, , 7-16.		0
94	The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1221-1227.	3.7	119
95	Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. <i>Human Pathology</i> , 2005, 36, 250-261.	2.0	157
96	The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: A fluorescence in situ hybridization study. <i>Human Pathology</i> , 2005, 36, 348-356.	2.0	61
97	The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. <i>Clinical Cancer Research</i> , 2005, 11, 186-92.	7.0	138
98	In situ hybridization in the pathology laboratory: General principles, automation, and emerging research applications for tissue-based studies of gene expression. <i>Journal of Molecular Histology</i> , 2004, 35, 595-601.	2.2	12
99	Mechanisms of TNF- α and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 821-831.	8.2	271
100	Mechanisms of TNF- α and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 821-831.	8.2	489
101	Bone morphogenetic protein-7 in growth-plate chondrocytes: Regulation by retinoic acid is dependent on the stage of chondrocyte maturation. <i>Journal of Orthopaedic Research</i> , 1998, 16, 247-255.	2.3	34
102	Interleukin-10 inhibits cytokine synthesis in monocytes stimulated by titanium particles: Evidence of an anti-inflammatory regulatory pathway. <i>Journal of Orthopaedic Research</i> , 1998, 16, 697-704.	2.3	26
103	Differential regulation of type-II and type-X collagen synthesis by parathyroid hormone-related protein in chick growth-plate chondrocytes. <i>Journal of Orthopaedic Research</i> , 1997, 15, 162-174.	2.3	52
104	P-glycoprotein expression in cartilaginous tumors. , 1997, 65, 95-105.		25
105	Extraosseous primary and recurrent giant cell tumors: Transforming growth factor- β 1 and - β 2 expression may explain metaplastic bone formation. <i>Human Pathology</i> , 1996, 27, 625-632.	2.0	43
106	Primary lymphoma of bone. Correlation of magnetic resonance imaging features with cytokine production by tumor cells. <i>Cancer</i> , 1995, 75, 973-980.	4.1	80
107	Shared phenotypic expression of osteoblasts and chondrocytes in fracture callus. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 533-544.	2.8	61
108	Regulation of osteoclastic activity in infection. <i>Methods in Enzymology</i> , 1994, 236, 47-58.	1.0	9

#	ARTICLE	IF	CITATIONS
109	Epithelioid osteosarcoma of bone immunocytochemical evidence suggesting divergent epithelial and mesenchymal differentiation in a primary osseous neoplasm. <i>Cancer</i> , 1993, 71, 2977-2982.	4.1	41